Novan Therapeutics is a clinical-stage biotech company focused on advancing nitric oxide therapies. Novan’s core technologies solve the previous delivery issues with nitric oxide by stably storing the gaseous species on macromolecules that result in a diverse pipeline of “timed-release” nitric oxide-releasing new chemical entities.  The company's proprietary platform technology enables drugable nitric oxide in a variety of dosage forms. 

Learn More

Nitric Oxide Topical Product Pipeline

In early 2014 Novan Therapeutics announced positive, statistically significant results of the Company’s Phase 2 study for the topical treatment of acne vulgaris with its lead drug candidate SB204.  These results support advancing SB204 into late stage clinical development as a first-in-class new acne treatment.  Additionally, Novan will leverage the safety data and study success to expand its platform.

Learn more